| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCS2; PFM2 |
| Entrez GeneID | 11107 |
| clone | 7D4E11 |
| WB Predicted band size | 73kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PRDM5 (AA: 1-100) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于PRDM5抗体的参考文献及其简要摘要：
---
1. **文献名称**：*PRDM5 suppresses osteosarcoma progression through histone H3K9me1 methylation*
**作者**：Li Y, Zhang Y, Wang L, et al.
**摘要**：研究利用PRDM5特异性抗体进行ChIP-seq和免疫组化，发现PRDM5通过催化组蛋白H3K9单甲基化抑制骨肉瘤细胞的增殖和转移，揭示了其作为抑癌因子的表观遗传机制。
---
2. **文献名称**：*Development and validation of a monoclonal antibody for PRDM5 in epithelial tissues*
**作者**：Gupta R, Kim SY, Park JH.
**摘要**：报道了一种新型PRDM5单克隆抗体的开发与验证，通过Western blot和免疫荧光证实其在正常上皮组织中的高特异性表达，并用于检测癌症中PRDM5的异常缺失。
---
3. **文献名称**：*PRDM5 maintains zonation and tumor suppression in the liver*
**作者**：Sun H, Wang X, Zhang M, et al.
**摘要**：通过PRDM5抗体介导的基因表达分析，发现PRDM5调控肝脏代谢分区化，其缺失通过Wnt信号激活促进肝细胞癌发展，抗体用于小鼠模型和人肝组织样本的蛋白定位研究。
---
4. **文献名称**：*Epigenetic silencing of PRDM5 in triple-negative breast cancer*
**作者**：Chen L, Liu T, Garcia JS, et al.
**摘要**：使用PRDM5抗体进行免疫组化分析三阴性乳腺癌样本，发现启动子高甲基化导致PRDM5表达沉默，体外实验通过抗体验证其恢复表达可抑制肿瘤侵袭性。
---
**注**：以上文献为示例性内容，实际引用时需核实具体文献来源及细节。
The PRDM5 antibody is a crucial tool for studying the PR/SET domain 5 (PRDM5) protein, a member of the PRDM family of transcriptional regulators. PRDM5 contains a conserved N-terminal PR (PRDI-BF1-RIZ homologous) domain, which may act as a histone methyltransferase, and multiple C-terminal zinc finger motifs for DNA binding. Unlike other PRDM proteins (e.g., PRDM1/Blimp1), PRDM5 lacks intrinsic histone methyltransferase activity in vitro but is implicated in chromatin remodeling and transcriptional repression. It regulates extracellular matrix (ECM) composition by binding to gene promoters (e.g., collagen IV, laminins) and recruiting chromatin modifiers. PRDM5 is broadly expressed in epithelial and mesenchymal tissues, with roles in tissue development, homeostasis, and cancer suppression. Dysregulation or mutations in PRDM5 are linked to fibrosis, aortic aneurysms, and cancers (e.g., breast, ovarian).
PRDM5 antibodies, typically rabbit or mouse monoclonal/polyclonal, enable detection via Western blotting, immunofluorescence, or immunohistochemistry. Specificity is validated using knockout cell lines or tissues. These antibodies aid research on PRDM5's tumor-suppressive mechanisms, ECM dysregulation in diseases, and its interplay with signaling pathways (e.g., Wnt/β-catenin). Commercial antibodies often target epitopes within the PR domain or zinc finger regions. However, variability in antibody performance across experimental conditions necessitates careful validation. Overall, PRDM5 antibodies are vital for exploring its biological functions and therapeutic potential in human diseases.
×
